Loading...
XLONSAR
Market cap42mUSD
Dec 27, Last price  
27.00GBP
1D
0.00%
1Q
1.89%
Jan 2017
-28.00%
Name

Sareum Holdings PLC

Chart & Performance

D1W1MN
XLON:SAR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.45%
Rev. gr., 5y
%
Revenues
0k
332,0001,476,0002,471,00000000000000047,2040000
Net income
-3m
L+7.14%
-1,243,000-624,000-527,000-1,692,000-1,074,000-569,000-568,000-650,563-539,131-762,873-1,255,368-1,048,118400,343-1,469,521-1,452,465-985,913-1,500,383-2,172,000-3,192,000-3,420,000
CFO
-4m
L+18.98%
-1,538,000-245,000-242,000-1,685,000-714,000-525,000-548,000-602,138-582,740-785,344-644,239-678,003843,870-1,592,323-1,263,230-813,087-1,570,658-2,131,000-3,267,000-3,887,000
Earnings
Mar 26, 2025

Profile

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
URL
https://sareum.com/
IPO date
Oct 11, 2004
Employees
5
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
4,633
2,910
4,359
Unusual Expense (Income)
NOPBT
(4,633)
(2,910)
(4,359)
NOPBT Margin
Operating Taxes
(1,182)
(833)
(407)
Tax Rate
NOPAT
(3,451)
(2,077)
(3,952)
Net income
(3,420)
7.14%
(3,192)
46.96%
(2,172)
44.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,375
3,708
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(1,459)
(1,040)
(4,284)
Cash flow
Cash from operating activities
(3,887)
(3,267)
(2,131)
CAPEX
(3)
Cash from investing activities
(23)
(41)
(2)
Cash from financing activities
4,375
3,708
FCF
(4,003)
(2,143)
(3,916)
Balance
Cash
1,459
994
4,261
Long term investments
46
23
Excess cash
1,459
1,040
4,284
Stockholders' equity
(23,020)
(19,772)
(16,594)
Invested Capital
25,134
20,903
20,907
ROIC
ROCE
EV
Common stock shares outstanding
80,993
68,069
67,679
Price
Market cap
EV
EBITDA
(4,632)
(2,909)
(4,357)
EV/EBITDA
Interest
1,000
Interest/NOPBT